The speaker wishes for the FDA approval of Bemotrizinol, a sunscreen ingredient used in Europe that effectively blocks UVA/UVB without leaching into the blood.

Instead of focusing on HDL, a better and still free marker for cardiovascular risk is non-HDL cholesterol, which should ideally be below 130 mg/dL.

Despite its online popularity, the majority of randomized controlled trials on Vitamin K2 (MK-7) for cardiovascular health show no effect on arterial or calcified plaque.

Contrary to fears about restricting it, preclinical studies suggest that increasing glycine intake may actually help fight cancer by starving cancer cells of carbon atoms needed for DNA synthesis.

Sunscreen blocks harmful UV radiation but does not block beneficial red light, allowing you to get the positive effects of sunlight while mitigating the aging and cancer risks.

The speaker questions whether inhibiting plaque calcification is always desirable, as the alternative could be more dangerous and unstable soft plaque.

While preclinical data suggests lithium orotate is superior for brain health, all human clinical trials showing a benefit have used other lithium salts like carbonate or sulfate.

The benefit of taking 600mg of berberine daily for two years to reduce colorectal cancer risk was shown to persist for six years after stopping the supplement.

HDL cholesterol is no longer considered a primary target for health improvement, as multiple drugs designed to raise it failed to reduce cardiovascular events in trials.